PROCYSBI (mercaptamine bitartrate): Reviews and patient testimonials
Medication indications
PROCYSBI 25 mg gastro-resistant hard capsules
PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
PROCYSBI 75 mg gastro-resistant hard capsules
PROCYSBI is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.
Route of administration: Oral
Molecule: mercaptamine bitartrate
Patients' opinions on PROCYSBI
In brief
General satisfaction level: Be the first to evaluate
Treatment's effectiveness: Be the first to evaluate
Ease of use: Be the first to evaluate
Adherence to prescription: Be the first to evaluate
Detected side effects: Be the first to evaluate
Improvement in the quality of life: Be the first to evaluate
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community
Join Carenity and be the first to give your opinion on this medication.